Abstract Details

Title Regionally Specific Cortical Thinning Predicts Conversion to Dementia in Prodromal Frontotemporal Dementia (FTD)

Topic Aging and Dementia

Presentation(s) P05 - (-)

Poster/Presentation
Number 103

Objective

Background BACKGROUND: Although many investigators believe that most neurodegenerative dementias have an initial symptomatic phase consistent with MCI, there has been relatively little study of non-Alzheimer forms of MCI. This prodromal stage could be an important window for therapeutic intervention.

Design/Methods DESIGN/METHODS: A consecutive series of patients with a clinical diagnosis of FTD was evaluated comprehensively, including functional assessment to determine whether the overall clinical status was best defined as MCI or dementia. MRI-derived cortical thickness analysis was employed to measure regional atrophy. Regions of interest were defined from our FTD-Signature of cortical atrophy, as identified in an independent sample of patients with frontotemporal dementia.

Results RESULTS: 34 patients were identified as having a clinical status of MCI, brain MRI available for cortical thickness analysis, and at least 1 follow up assessment. The majority (28) had one of the aphasic phenotypes as opposed to behavioral variant FTD (bvFTD). Of the 34 MCI patients, 17 have since converted to dementia. Baseline cortical thickness of the FTD-Sig demonstrated greater atrophy in the converters compared to non-converters (p < 0.05).

Conclusions CONCLUSIONS: In our experience, it is relatively common for aphasic FTD but not bvFTD to present in a prodromal clinical phase consistent with MCI. The FTD-Signature comprises a set of cortical regions which exhibit significant atrophy in the prodromal stages of frontotemporal dementia. Additional analyses are underway to identify the best clinical predictors of conversion to dementia.

Authors/Disclosures
Kimiko Domoto-Reilly, MD PRESENTER	Dr. Domoto-Reilly has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MedBridge. The institution of Dr. Domoto-Reilly has received research support from Lawson Health Research Institute. The institution of Dr. Domoto-Reilly has received research support from NIH. The institution of Dr. Domoto-Reilly has received research support from Biogen. The institution of Dr. Domoto-Reilly has received research support from Lewy Body Dementia Association. The institution of Dr. Domoto-Reilly has received research support from Garvey Institute for Brain Health Solutions. The institution of Dr. Domoto-Reilly has received research support from Cognition Therapeutics. The institution of Dr. Domoto-Reilly has received research support from Takayama Family.
	No disclosure on file
	No disclosure on file
Scott McGinnis, MD (Brigham and Women'S Hospital)	Dr. McGinnis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai.
Bruce A. Cree, MD, PhD, MAS, FAAN (UCSF, Multiple Sclerosis Center)	The institution of Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neuron23. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Pharma. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hexal/Sandoz. Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic AG. The institution of Dr. Cree has received research support from Genentech. The institution of Dr. Cree has received research support from Kyverna. Dr. Cree has received publishing royalties from a publication relating to health care.
	No disclosure on file
Bradford Dickerson, MD, FAAN	Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arkuda. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lantheus. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Dickerson has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arkuda. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Dickerson has received publishing royalties from a publication relating to health care. Dr. Dickerson has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��